Drugs / BGB-B167
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05644626 | Mar 2024 → Mar 2025 | cancer | BeiGene | Withdrawn | No outcome recorded |
| Phase 1 | NCT05494762 | Aug 2022 → Feb 2025 | cancer | BeiGene | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | BeOne Medicines | Results BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 beonemedicines.com ↗
BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and in vivo anti-tumor activity and superior safety profile in preclinical models |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | BeOne Medicines | BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 beonemedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-B167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05494762 ↗ |
| Route | Intravenous | “Intravenous administration” NCT05494762 ↗ |